Biogen Inc. (Nasdaq: BIIB) is rolling out its commercialization plan for its newly approved Alzheimer’s drug, Aduhelm, immediately. The company says it is poised to begin shipping the drug two weeks from now, to an estimated 900 clinical sites.
Read More
